Gilead Sciences Inc

The CoinUnited GILD instrument is a contract for difference (CFD) that provides leveraged price exposure to Gilead Sciences stock. It does not confer shareholding, voting rights, or any dividend entitlement; the position is purely a price-return contract on the underlying equity.

Understanding the instrument's mechanics, fee structure, session hours, and leverage specification is essential before placing a trade.

Instrument Mechanics

A CFD position on GILD rises and falls in line with the Gilead Sciences share price. Profit and loss are calculated on the notional exposure controlled by the position, not on the margin deposited. The difference between entry and exit price, multiplied by the notional size, determines the realised P&L.

Because the instrument is derivative in nature, traders gain directional exposure without holding the underlying security.

Accounts on CoinUnited are funded and withdrawn in crypto. No traditional bank account is required for access.

Session Hours and Weekend Gap Risk

The GILD CFD follows a scheduled trading session. It is closed at weekends and observes US market holidays. This is a material operational point: the instrument trades during defined market hours and does not operate on weekends or public holidays.

Weekend gap risk is a direct consequence of this structure. Any material news released between Friday's close and Monday's open — an FDA action, a clinical data readout, an M&A announcement, or an unexpected earnings revision — will be reflected in the price at reopening, with no opportunity to adjust the position in the interim.

For a stock with Gilead's catalyst calendar, this risk is far from theoretical. GILD closed at $165.61 on October 29, 2026, then moved to $168.91 in after-hours trading following a strong Q3 earnings release. A gap of that magnitude occurring across a weekend session boundary would leave leveraged positions unable to respond until the Monday open.

Positions held across a weekend near any scheduled catalyst carry elevated gap exposure.

Confirm the exact session schedule and holiday calendar on the platform before entering any position.

Fee Structure

CoinUnited charges a trading fee on this market. The standard-tier rate is not zero. Fees follow a nine-level VIP tiered structure, where the rate decreases as 30-day contract volume rises. The 0.000% rate applies only at VIP 9, which requires a 30-day trading volume of 20,000,000,000 USDT or an account balance of 200,000,000 USDT. For most traders, a positive fee rate applies to every trade.

For leveraged strategies that involve frequent entries and exits around catalysts — a common approach in pharma trading — cumulative fees across multiple round trips can meaningfully affect net returns. The live rate applicable to your account tier is displayed on the platform and at the fee schedule page.

Leverage Specification

The maximum leverage available on the GILD CFD is 1000x, subject to product terms, jurisdiction, and account eligibility. Leverage amplifies both gains and losses proportionally, and positions can be liquidated before an adverse move reaches its full extent.

The arithmetic is exact and unforgiving. Consider the following hypothetical:

A 0.1% adverse move against a 1000x position eliminates 100% of the margin. At this leverage level, a 1% adverse move produces a 1000% loss on margin; liquidation occurs well before that threshold is reached. Position sizing must account for the distance between the entry price and the liquidation price, which compresses dramatically at high leverage multiples.

Pharma-Specific Strategy Considerations

Gilead's catalyst calendar introduces a category of risk that requires adjustment beyond standard leverage-management practice. Binary regulatory and clinical events — PDUFA dates, advisory committee outcomes, phase III data releases — can produce price gaps that exceed the buffer built into any leveraged position sized for normal volatility.

Several operational points apply specifically to GILD heading into late 2026:

Around earnings and guidance revisions: Gilead reported Q3 2026 total product sales of $8.3 billion, up 13% year over year, and raised its full-year 2026 total product-sales guidance to $31.0 billion–$31.3 billion. GILD closed at $165.61 on October 29 before moving to $168.91 after hours.

That kind of earnings-driven gap — occurring after the close and therefore spanning into the next session open — illustrates why holding leveraged positions into scheduled results carries asymmetric risk in either direction.

Pipeline and M&A events: Gilead acquired PepStar's HCXT-2001, an oral anti-IL-23 Phase 1 candidate, for $1.275 billion in October 2026, extending its IBD platform strategy. Earlier in the year, Gilead completed a $5 billion acquisition of ADC biotech Tubulis GmbH and signed a $750 million licensing deal for KT-200, a molecular glue degrader.

Each announcement introduced a short-term repricing event. M&A-driven gaps are not confined to adverse outcomes — a confirmed deal can move the stock 3–5% intraday, and a denial or deal-fade can reverse that move rapidly against overextended leveraged positions.

Analyst targets relative to price: With GILD trading above $165 and Jefferies carrying a $185 price target (Buy, raised in October 2026), the stock has meaningful upside priced in by some analysts. However, beta calculated on historical data does not capture the discontinuous price behaviour that accompanies binary FDA decisions or surprise M&A disclosures.

Low implied volatility on a quiet week does not imply low event risk.

Traders monitoring the broader Pharma & Fintech Acquisition Repricing environment may also consider how sector-level M&A sentiment affects Gilead's valuation multiple, independent of its pipeline catalysts.

Gilead Sciences occupies a distinct position within the large-cap biopharmaceutical sector, defined less by breadth of therapeutic coverage and more by depth of franchise concentration.

Unlike diversified peers such as Johnson & Johnson or AbbVie Inc., which carry revenues across immunology, medical devices, consumer health, and surgical technologies, Gilead's commercial base remains heavily anchored in antiviral and HIV products.

That concentration has historically produced a stable, recurring cash-flow profile, though it also means that franchise-specific risks, patent cliffs, competitive launches, or treatment-guideline shifts, carry proportionally greater weight.

HIV Franchise: A Comparable Transition Model

The strategic challenge Gilead faces in HIV parallels the biosimilar erosion AbbVie navigated with Humira. AbbVie's response was to accelerate uptake of next-generation immunology products, Skyrizi and Rinvoq, to offset Humira revenue loss as biosimilar competition intensified.

Gilead is executing an analogous transition in HIV: migrating patients from older regimens toward newer combinations, with lenacapavir-based therapies at the centre of that upgrade cycle. The twice-yearly injectable format of lenacapavir creates a differentiated patient experience relative to daily oral alternatives, which may support switching rates and premium pricing over time.

Q3 2026 results provide early evidence of traction: HIV product sales reached $6.25 billion in the quarter, up 18% year over year, supported by Biktarvy, Descovy, and the commercial ramp of Yeztugo, which is tracking toward approaching $1 billion in full-year 2026 sales.

Whether Gilead replicates AbbVie's successful transition at comparable scale is a question analysts continue to model with varying assumptions, though the Q3 growth rate lends weight to the more constructive scenarios.

Oncology: Building Scale Against Established Players

In oncology, Gilead competes in the antibody-drug conjugate space, a segment where several large-cap peers have established multi-product franchises. Trodelvy posted $506 million in Q3 2026 sales, a 42% year-over-year increase, representing a material step forward in Gilead's oncology revenue contribution and expanding both the addressable patient population and geographic commercial reach.

Gilead has also moved aggressively to deepen its ADC pipeline. The $5 billion acquisition of Tubulis GmbH, which secured a clinical-stage ADC targeting ovarian cancer alongside a next-generation ADC platform, closed in Q2 2026, while the April 2026 licensing of KT-200 from Kymera added a molecular glue degrader expected to enter clinical trials with a 2027 IND filing.

Cell-therapy sales, by contrast, declined 18% to $355 million in Q3, highlighting competitive pressure that partially offsets oncology progress elsewhere.

The oncology buildout is a medium-term revenue opportunity moving toward greater earnings relevance, and the Pharma & Fintech Acquisition Repricing environment continues to influence how the market values pipeline-dependent growth across the sector.

Analyst Consensus and Institutional Positioning

Q3 2026 product sales of $8.3 billion, up 13% year over year, prompted Gilead to raise its full-year 2026 total product-sales guidance to $31.0 billion–$31.3 billion, from a prior forecast of $30.1 billion–$30.4 billion.

The guidance revision reduces the uncertainty that had introduced dispersion in analyst models earlier in the year, and Jefferies responded in late October 2026 by raising its price target modestly to $185 (Buy), reflecting measured optimism rather than a major thesis upgrade.

A Moderate Buy rating in large-cap pharma typically signals that the market broadly recognises the franchise value while requiring clarity on one or more execution questions before moving to a more uniformly bullish stance.

Institutional ownership remains consistent with GILD maintaining relevance in large-cap healthcare allocations as of October 2026.

This is a positioning observation rather than a directional signal: large-cap pharma names with market capitalisations in this range are standard components of diversified healthcare mandates, and institutional presence reflects inclusion criteria as much as active conviction.

Relative Positioning Summary

Gilead's franchise stability remains conditional on the HIV transition continuing to execute — Q3 2026 data suggests it is — while oncology revenues, led by Trodelvy, grow to meaningful scale and cell-therapy headwinds are managed. The raised full-year guidance to $31.0 billion–$31.3 billion reflects management's own confidence in sustaining that trajectory through year-end.

Gilead Sciences attracts attention from speculative and fundamental traders for a specific combination of reasons: a durable, cash-generating HIV franchise that provides revenue predictability, a pipeline of regulatory catalysts concentrated enough to create sharp near-term price moves, and a beta profile that insulates the stock from most macro noise while making it acutely sensitive to its own

news flow. For a CFD trader taking leveraged price exposure, understanding what actually moves GILD, and what does not, is the starting point for any position framework.

The Bull Case: Franchise Durability and Pipeline Optionality

The structural bull case for GILD rests on two pillars. The first is the HIV franchise. Q3 2026 HIV product sales rose 18% year over year to $6.2 billion, a pace that underscores the franchise's continued momentum rather than maturity. Lenacapavir (Yeztugo), approved as a twice-yearly injectable PrEP option, addresses a large and historically underserved prevention market.

Daily oral adherence has been a persistent barrier to PrEP uptake globally; a twice-yearly dosing schedule changes the compliance calculus materially.

Looking further ahead, Gilead expects to file an islatravir-plus-lenacapavir combination with the FDA during 2026, with a potential regulatory decision in 2027 — a once-weekly oral option for virally suppressed patients that could further extend the franchise's reach.

The second pillar is Trodelvy in oncology. Sales of $506 million in Q3 2026 represented 42% year-over-year growth, confirming Trodelvy as a genuine second commercial growth engine operating independently of antiviral revenues.

Gilead also announced the opening of a new research centre focused on oncology, inflammation, and research data science as part of a planned $32 billion U.S. research, development, and manufacturing investment through 2030, signalling long-term commitment to the oncology build.

The oncology expansion is also consistent with broader Pharma & Fintech Acquisition Repricing trends, where deal valuations across the pharmaceutical sector have been recalibrated around pipeline depth and regulatory velocity.

Recent bolt-on activity — including the $5 billion Tubulis ADC acquisition and an exclusive licence for KT-200, a molecular glue degrader targeting a 2027 IND filing — further deepens this pipeline.

Near-Term Catalysts: Regulatory Binary Events and Guidance

For the short-to-medium term, regulatory decisions remain the dominant catalyst type. Binary outcomes — approval or a Complete Response Letter — tend to produce asymmetric single-session price moves. The pending FDA filing for islatravir plus lenacapavir is the most visible upcoming regulatory event on Gilead's HIV calendar.

For a leveraged CFD position, this asymmetry cuts in both directions: a positive outcome could generate a rapid upward move, while an adverse decision would likely produce a sharp drawdown. Position sizing ahead of a PDUFA date should account for the possibility of a gap move that cannot be exited at an intermediate price.

Gilead raised its 2026 full-year product-sales guidance to $31.0–$31.3 billion after Q3 results, up from the prior range of $30.1–$30.4 billion. Q3 adjusted EPS of $2.55 on $8.3 billion of revenue materially beat analyst estimates of $2.19 and $7.8 billion respectively, demonstrating the operating leverage embedded in the franchise at scale.

Traders should verify the session and holiday calendar on the platform before trading around any scheduled regulatory or earnings event. This instrument follows scheduled trading sessions and is closed at weekends and on market holidays, making weekend gap risk a genuine consideration — particularly when significant news breaks outside market hours.

Interpreting the Q3 2026 EPS Swing and Deal-Related Charges

Gilead raised its 2026 adjusted-loss guidance to $0.85–$1.20 per share in the same quarter that product sales surged 13% year over year to $8.3 billion. The disconnect is explained by $12.4 billion in deal-related charges — a scale of exceptional item that is not an operating deterioration signal.

The more common drivers are goodwill impairment following an acquisition reassessment, in-process R&D write-offs, or transaction costs from the active M&A programme. Assessing the earnings trajectory requires separating these charges from recurring operating income; the Q3 adjusted EPS of $2.55 provides a cleaner read on underlying profitability.

Until the composition and duration of deal charges are fully attributed, they introduce genuine uncertainty about the path to GAAP earnings normalization.

Beta and Macro Sensitivity

Gilead's historically low equity beta implies that broad-market swings have a muted direct effect on GILD's price. During periods when macro catalysts — Fed rate decisions, inflation prints, or equity-index volatility — dominate market headlines, GILD tends to be relatively insulated.

The Fed & ECB Rate Patience Macro Repricing environment that has characterized much of 2026 may therefore have a more muted direct effect on GILD than on higher-beta names. The corollary is that GILD's price action is disproportionately driven by its own pipeline and earnings news, a dynamic that Q3 results confirmed in real time.

Key Risk Factors

The risk profile for a leveraged GILD position includes several distinct categories:

The low beta provides some buffer against macro-driven drawdowns, but it does not dampen the stock's sensitivity to idiosyncratic events. Regulatory decisions, trial readouts, and quarterly results can each produce single-session moves that dwarf any macro-driven daily range, and leverage amplifies all of them.

Trading fees apply to every position opened on this instrument; the fee structure is tiered by 30-day contract volume and reaches 0.000% only at VIP 9 — the standard tier is not free. The full fee schedule and available VIP tiers are detailed at coinunited.io/en/account/trading-fees.